Basu P, Biswas J, Mandal R, Choudhury P
Department of Gynecologic Oncology, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata, India.
Indian J Cancer. 2006 Apr-Jun;43(2):54-9. doi: 10.4103/0019-509x.25885.
Locally advanced cervical cancers comprise a large majority of the gynecologic cancers in India and other developing countries. Concurrent chemo-radiation has improved the survival of high risk stage I and stage II cervical cancers. There is no evidence that the same survival benefit has been achieved with chemo-radiation in stage III and stage IV disease. Interferon-alpha and Retinoic acid have synergistic anti-proliferative activity. In combination with radiation, they substantially enhance the sensitivity of the squamous carcinoma cells to radiation. Based on these observations from the in vitro studies, a few clinical trials have evaluated the combination of interferon-alpha and Retinoic acid, concomitant with radiation, to treat cervical cancers. The results from these early trials were encouraging and the combination had minimal toxicities. However, till date, no phase III randomized controlled trial has been done to evaluate this therapeutic modality.
局部晚期宫颈癌在印度和其他发展中国家的妇科癌症中占大多数。同步放化疗提高了高危I期和II期宫颈癌的生存率。没有证据表明放化疗对III期和IV期疾病能带来同样的生存获益。α-干扰素和视黄酸具有协同抗增殖活性。与放疗联合使用时,它们能显著增强鳞状癌细胞对放疗的敏感性。基于这些体外研究的观察结果,一些临床试验评估了α-干扰素和视黄酸与放疗同时使用治疗宫颈癌的效果。这些早期试验的结果令人鼓舞,且该联合治疗的毒性极小。然而,迄今为止,尚未进行III期随机对照试验来评估这种治疗方式。